New study tests if trikafta helps CF patients breathe easier during exercise
NCT ID NCT05279040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 20 adults with cystic fibrosis who are starting Trikafta to see if it reduces shortness of breath and improves exercise performance over two years. Participants will do exercise tests and report their breathing symptoms. The goal is to understand how this medication affects daily life and physical activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UBC Centre for Heart Lung Innovation, St. Paul's Hospital
RECRUITINGVancouver, British Columbia, V6Z 1Y6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cutting radiation in CT scans: a new test of Ultra-Low-Dose imaging
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?